Adolescents who met criteria for anorexia nervosa or bulimia nervosa were 2.4 and 1.9 times, respectively, more likely to seek treatment than adolescents who met criteria for binge-eating disorder.
Syndros is anticipated to launch in the second half of 2017. It will be available as a 5mg/mL strength oral solution.
For select patients, psychostimulants may be beneficial for treating bulimia nervosa, according to a study of six cases published online January 23 in the Journal of Clinical Pharmacology.
Seventeen percent of high school students say they have engaged in non-medical use of prescription drugs (NMUPD), according to a recent Youth Risk Behavior Survey.
The FDA has approved Syndros (dronabinol oral solution) for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Women with eating disorders more often exhibit risky drinking behaviors than their unaffected peers, according to a study published online April 1 in the International Journal of Eating Disorders.
Mortality is increased among patients with eating disorders, with higher mortality for those with anorexia nervosa (AN) compared with bulimia nervosa (BN), binge eating disorder (BED), and eating disorder not otherwise specified (ED-NOS), according to a study published online in the International Journal of Eating Disorders.
For adults with severe anorexia nervosa (AN), elevated liver enzymes are relatively common and are associated with lower body mass index (BMI) and hypoglycemia.
Smoking cessation may be associated with resurgence of anorexic symptoms in patients with a history of anorexia nervosa.
Recent research has shown that an increasing number of men are using over-the-counter bodybuilding supplements to the point where it may be characterized as an eating disorder.
